In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.66 million shares changing hands with its beta currently measuring 1.49. Company’s recent per share price level of $1.15 trading at $0.01 or 0.88% at ring of the bell on the day assigns it a market valuation of $428.10M. That closing price of LAB’s stock is at a discount of -164.35% from its 52-week high price of $3.04 and is indicating a premium of 13.91% from its 52-week low price of $0.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.11 million shares which gives us an average trading volume of 1.99 million if we extend that period to 3-months.
For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Standard BioTools Inc (NASDAQ:LAB) trade information
Upright in the green during last session for gaining 0.88%, in the last five days LAB remained trading in the red while hitting it’s week-highest on Thursday, 03/06/25 when the stock touched $1.15 price level, adding 6.5% to its value on the day. Standard BioTools Inc’s shares saw a change of -34.29% in year-to-date performance and have moved -4.17% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of -12.21% in past 30-days. Number of shares sold short was 14.17 million shares which calculate 6.28 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 64.62% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -182.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -182.61% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.61% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 65.38% while estimates for its earnings growth in next 5 years are of 57.47%.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Insiders are in possession of 1.89% of company’s total shares while institution are holding 74.43 percent of that, with stock having share float percentage of 75.87%. Investors also watch the number of corporate investors in a company very closely, which is 74.43% institutions for Standard BioTools Inc that are currently holding shares of the company. CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.
The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 9.17 shares of worth $10.55 million or 2.46% of the total outstanding shares. The later fund manager was in possession of 7.94 shares on Dec 31, 2024 , making its stake of worth around $9.13 million in the company or a holder of 2.13% of company’s stock.
